ArticleACS pharmacology & translational science2019

Revealing Metabolic Liabilities of Ralaniten To Enhance Novel Androgen Receptor Targeted Therapies.

Jon K Obst et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.